1984 headquarters marlborough massachusetts united states key people nobuhiko tamura chairman and chief executive officer antony loebel m.d. executive vice president chief medical officer head of global clinical development greg bokar senior vice president legal affairs and corporate secretary david frawley senior vice president chief commercial officer robert gregorio executive vice president chief administrative officer matthew d ambrosio senior vice president chief compliance and ethics officer stephen freeman senior vice president chief financial officer products latuda aptiom brovana lunesta xopenex omnaris alvesco zetonna parent dainippon sumitomo pharma website http www.sunovion.com sunovion pharmaceuticals inc. former nasdaq sepr known until october 12 2010 as sepracor inc. prior to its acquisition by dainippon sumitomo pharma of japan 1 is a pharmaceutical company founded in 1984 by timothy j. barberich steve matson and bob bratzler . it was originally located in princeton new jersey and then re located to marlborough massachusetts . 2 in addition to its headquarters location in marlborough massachusetts sunovion has locations in london england mississauga ontario canada and fort lee new jersey . contents 1 company history 1.1 acquisition by dainippon sumitomo 2 beneficiaries partners and subsidiaries 2.1 eslicarbazepine acetate 2.2 omnaris and alvesco 3 references 4 external links company history edit the company s initial focus was on the development of single isomers and active metabolites . this concept allowed barberich and doug reedich to generate a patent estate that served the company well for many years . therapeutically sepracor s products were focused on the treatment of central nervous system and respiratory disorders under the direction of gunnar aberg and john mccullough . the primary source of its revenue was the approximately 600 million annually from its xopenex franchise of drugs launched under the marketing leadership of john simon with the direct involvement of medical communications under dean handley . it is available as a multi dose inhaler mdi or nebulized udv form . the insomnia drug lunesta eszopiclone was discovered by tom jerussi approved by the us food and drug administration fda in december 2004 and launched in april 2005 under the marketing leadership of tim healy . on february 13 2006 sepracor filed a new drug application for brovana patented by gunnar aberg and john morley also launched under john simon to treat chronic obstructive pulmonary disease . all of the launch drugs were manufactured under the leadership of walter piskorski . citation needed in september 2016 the company announced it would acquire cynapsus therapeutics for approximately 624 million specifically expanding sunovians central nervous system drug portfolio . through the deal sunovion would acquire cynapsus phase iii parkinson s disease candidate drug apl 130277 . 3 acquisition by dainippon sumitomo edit on september 2 2009 shares of sepracor were halted on the nasdaq due to pending news of a takeover bid by japanese drugmaker dainippon sumitomo . according to the associated press dainippon planned to offer 2.6 billion for sepracor a nearly 28 % premium over the stock s closing price on september 1 . 4 aside from acquiring such drugs as lunesta and xopenex analysts said the acquisition would give dainippon access to sepracor s sales force of roughly 1 200 which would open an avenue for the japanese company to market its drugs in the united states . 5 sepracor was set to face stiff generic competition from its expiring patents xopenex in 2012 and lunesta in 2014 and had failed to discover any viable drugs in nearly 10 years . 6 7 a formal announcement of the acquisition was made on october 12 2010 which stated that sunovion would be an indirect wholly owned subsidiary of dainippon sumitomo pharma co. ltd. 1 beneficiaries partners and subsidiaries edit eslicarbazepine acetate edit in 2008 bial agreed with sepracor that its antiepileptic eslicarbazepine acetate trade name aptiom would be produced in sepracor s facilities and supervised by bial . 8 omnaris and alvesco edit the company acquired omnaris and alvesco for 150m upfront and an addition 280m in potential milestones . alvesco revenues for q4 08 were 0.3 million because returns from the stocking in q3 08 exceeded the demand in q4 08 . the company disclosed a 2009 forecast of 25 40m for omnaris and 10 15m for alvesco ; yielding a combined total of 35m 55m in year 2 of a launch . however revenues continue to be dismal prompting criticisms and concerns over the purchase price relative to minuscule income . references edit a b company press release sepr profile for sepracor inc yahoo finance sunovion to acquire cynapsus for 624m gen news highlights gen . http finance.yahoo.com news dainippon of japan acquires apf 3135825802.html x 0 & sec topstories & pos 3 & asset & ccode tse suspends trade in dainippon sumitomo pharma . 2 september 2009 via reuters . drugmaker sepracor accepts 2.6 b buyout offer from japan s dainippon xconomy . 3 september 2009 . aol . finance news & latest business headlines from aol . bial caring for your health . external links edit sunovion pharmaceuticals inc. retrieved from https en.wikipedia.org w index.php title sunovion & oldid 737417440 categories companies formerly listed on nasdaqbiotechnology companies of the united statescompanies based in middlesex county massachusettsmarlborough massachusettscompanies established in 1984hidden categories all articles with unsourced statementsarticles with unsourced statements from may 2009 navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page print export create a bookdownload as pdfprintable version languages fran ais edit links this page was last modified on 2 september 2016 at 17 02 . text is available under the creative commons attribution sharealike license ; additional terms may apply . by using this site you agree to the terms of use and privacy policy . wikipedia is a registered trademark of the wikimedia foundation inc. a non profit organization . privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view